RESUMEN
OBJECTIVE: To describe the time point prevalence and distribution of all types of mental disorders in Hebei Province. METHODS: From October 2004 to March 2005, stratified multi-stage cluster randomization was used to identify 24,000 subjects ≥18 years of age in Hebei Province. An expanded version of the General Health Questionnaire (GHQ-12) was used to identify subgroups of subjects at high, moderate and low risk of having a mental disorder, then psychiatrists determined their diagnoses by administering a structured psychiatric examination (SCID) that employs Diagnostic and Statistical Manual of Mental Disorder (DSM-IV). RESULTS: (1) Twenty thousand seven hundred and sixteen subjects completed the screening. The overall time point rate of mental disorders was 16.24% (95% CI=15.8-16.7%). Major depressive disorder (2.70%), unspecified anxiety disorders (2.51%) and dysthymic disorders (2.31%) occupied the preceding positions. The overall life-time prevalence of mental disorders was 18.51% (95% CI=18.0-19.0%). Major depressive disorder (4.75%), alcohol dependence and abuse disorders (3.86%) and unspecified depressive disorder (2.55%) occupied the preceding positions. (2) The time point prevalence: the overall prevalence of mental disorders was higher in rural (16.65%) than in urban areas (14.43%) and obviously higher in women (16.79%) than in men (15.70%), P<0.05-0.01. Accompanied with the age growth, the prevalence goes up. Among the total, 30-49 was 137.17-156.71, ≥50 was 20.14-28.54%. CONCLUSIONS: Through the investigation, we have kept abreast of the time point prevalence and the characteristic of distribution of all types of mental disorders in Hebei Province, and provide scientific basis for the prevention and treatment of mental disorders.
RESUMEN
Objective To explore the effects of low-dose mifepristone on human granulosa cells and the molecular mechanism of its inhibiting or delaying ovulation.Methods Phase contrast microscopy and electron microscopy were conducted to observe the morphological and biochemical change of granulosa cells exposed to various doses of mifepristone for 24 hours(the final concentrations of mifepristone were respectively 2.5?mol/L,5?mol/L and 10?mol/L,Non-mifepristone as the control group).Immunocytochemistry was performed to detect the protein expressions of Bcl-2 and Bax in granulosa cells exposed to various doses of mifepristone for 24 hours.The mRNA levels of Bcl-2 and Bax in granulosa cells were detected by RT-PCR.Results Granulosa cells treated with various doses of mifepristone presented typical morphological characteristics of apoptosis such as condensation of chromatin and cytosolic,and shrink of cells.The expression of Bcl-2 protein might be down-regulated,while the expression of Bax might be up-regulated by mifepristone.The histological score(HSCORE) of Bcl-2 protein in granulosa cells,which were incubated with various doses of mifepristone(2.5?mol/L,5?mol/L,10?mol/L) for 24 hours,were respectively 2.15?0.16,1.88?0.13 and 1.64?0.16 respectively,Compared with the HSCORE of the control group(2.51?0.16),the difference was significant(P0.05).Conclusion Mifepristone could induce human granulosa cells apoptosis.The Bcl-2 protein and Bax protein may be involved in the apoptosis of granulosa cells induced by mifepristone.
RESUMEN
AIM:To investigate the effect of different low-dose mifepristone on apoptosis in granulosa cells and to test low-dose mifepristone as an orally contraceptive drug.METHODS:By using immunofluorescence,terminal deoxynucleotidyl transferase-mediated nick end labelling(TUNEL)and flow cytometry technique,the nuclear morphologic features and ratio of apoptosis and fluorescent intensity of caspase-3 in granulosa cells cultured in vitro treated with different low-doses of mifepristone were observed,respectively.RESULTS:By the display of immunofluorescence,the granulosa cells in treatment group were classified as apoptotic cells on the basis of their morphologic features contained a single condensed chromatin,multiple nuclear fragments.The results of TUNEL showed significant difference between control group and groups treated with different concentration of mifepristone(P